Community  ||| S:0 E:10 ||| NNP
treatment  ||| S:10 E:20 ||| NN
orders  ||| S:20 E:27 ||| NNS
and  ||| S:27 E:31 ||| CC
antipsychotic  ||| S:31 E:45 ||| JJ
long-acting  ||| S:45 E:57 ||| JJ
injections  ||| S:57 E:68 ||| NNS
The  ||| S:68 E:72 ||| DT
community  ||| S:72 E:82 ||| NN
treatment  ||| S:82 E:92 ||| NN
order  ||| S:92 E:98 ||| NN
( ||| S:98 E:99 ||| -LRB-
CTO ||| S:99 E:102 ||| NNP
)  ||| S:102 E:104 ||| -RRB-
is  ||| S:104 E:107 ||| VBZ
the  ||| S:107 E:111 ||| DT
legal  ||| S:111 E:117 ||| JJ
framework  ||| S:117 E:127 ||| NN
by  ||| S:127 E:130 ||| IN
which  ||| S:130 E:136 ||| WDT
people  ||| S:136 E:143 ||| NNS
in  ||| S:143 E:146 ||| IN
the  ||| S:146 E:150 ||| DT
community  ||| S:150 E:160 ||| NN
are  ||| S:160 E:164 ||| VBP
compelled  ||| S:164 E:174 ||| VBN
to  ||| S:174 E:177 ||| TO
accept  ||| S:177 E:184 ||| VB
treatment ||| S:184 E:193 ||| NN
.  ||| S:193 E:195 ||| .
Both  ||| S:195 E:200 ||| DT
antipsychotic  ||| S:200 E:214 ||| JJ
long-acting  ||| S:214 E:226 ||| JJ
injections  ||| S:226 E:237 ||| NNS
( ||| S:237 E:238 ||| -LRB-
LAIs ||| S:238 E:242 ||| NNP
)  ||| S:242 E:244 ||| -RRB-
and  ||| S:244 E:248 ||| CC
CTOs  ||| S:248 E:253 ||| NNS
are  ||| S:253 E:257 ||| VBP
used  ||| S:257 E:262 ||| VBN
to  ||| S:262 E:265 ||| TO
address  ||| S:265 E:273 ||| VB
treatment  ||| S:273 E:283 ||| NN
non-adherence ||| S:283 E:296 ||| NN
.  ||| S:296 E:298 ||| .
To  ||| S:298 E:301 ||| TO
investigate  ||| S:301 E:313 ||| VB
the  ||| S:313 E:317 ||| DT
relationship  ||| S:317 E:330 ||| NN
between  ||| S:330 E:338 ||| IN
CTOs  ||| S:338 E:343 ||| JJ
and  ||| S:343 E:347 ||| CC
LAI  ||| S:347 E:351 ||| NNP
use  ||| S:351 E:355 ||| NN
in  ||| S:355 E:358 ||| IN
patients  ||| S:358 E:367 ||| NNS
with  ||| S:367 E:372 ||| IN
schizophrenia ||| S:372 E:385 ||| NN
.  ||| S:385 E:387 ||| .
Prescribing ||| S:387 E:398 ||| NNP
,  ||| S:398 E:400 ||| ,
demographic  ||| S:400 E:412 ||| JJ
and  ||| S:412 E:416 ||| CC
CTO  ||| S:416 E:420 ||| NNP
data  ||| S:420 E:425 ||| NNS
were  ||| S:425 E:430 ||| VBD
collected  ||| S:430 E:440 ||| VBN
for  ||| S:440 E:444 ||| IN
patients  ||| S:444 E:453 ||| NNS
from  ||| S:453 E:458 ||| IN
four  ||| S:458 E:463 ||| CD
community  ||| S:463 E:473 ||| NN
mental  ||| S:473 E:480 ||| JJ
health  ||| S:480 E:487 ||| NN
clinics  ||| S:487 E:495 ||| NNS
in  ||| S:495 E:498 ||| IN
Melbourne ||| S:498 E:507 ||| NNP
,  ||| S:507 E:509 ||| ,
Australia ||| S:509 E:518 ||| NNP
,  ||| S:518 E:520 ||| ,
in  ||| S:520 E:523 ||| IN
1998  ||| S:523 E:528 ||| CD
and  ||| S:528 E:532 ||| CC
2002 ||| S:532 E:536 ||| CD
.  ||| S:536 E:538 ||| .
Against  ||| S:538 E:546 ||| IN
a  ||| S:546 E:548 ||| DT
background  ||| S:548 E:559 ||| NN
of  ||| S:559 E:562 ||| IN
increasing  ||| S:562 E:573 ||| VBG
use  ||| S:573 E:577 ||| NN
of  ||| S:577 E:580 ||| IN
oral  ||| S:580 E:585 ||| JJ
second-generation  ||| S:585 E:603 ||| JJ
antipsychotic  ||| S:603 E:617 ||| NNS
( ||| S:617 E:618 ||| -LRB-
SGA ||| S:618 E:621 ||| NNP
)  ||| S:621 E:623 ||| -RRB-
medication  ||| S:623 E:634 ||| NN
and  ||| S:634 E:638 ||| CC
decreasing  ||| S:638 E:649 ||| JJ
use  ||| S:649 E:653 ||| NN
of  ||| S:653 E:656 ||| IN
LAIs ||| S:656 E:660 ||| NNP
,  ||| S:660 E:662 ||| ,
the  ||| S:662 E:666 ||| DT
rates  ||| S:666 E:672 ||| NNS
of  ||| S:672 E:675 ||| IN
CTO  ||| S:675 E:679 ||| NNP
implementation  ||| S:679 E:694 ||| VBD
doubled  ||| S:694 E:702 ||| VBN
from  ||| S:702 E:707 ||| IN
13 ||| S:707 E:709 ||| CD
%  ||| S:709 E:711 ||| NN
to  ||| S:711 E:714 ||| TO
26 ||| S:714 E:716 ||| CD
%  ||| S:716 E:718 ||| NN
of  ||| S:718 E:721 ||| IN
patients  ||| S:721 E:730 ||| NNS
with  ||| S:730 E:735 ||| IN
schizophrenia  ||| S:735 E:749 ||| NN
between  ||| S:749 E:757 ||| IN
1998  ||| S:757 E:762 ||| CD
and  ||| S:762 E:766 ||| CC
2002 ||| S:766 E:770 ||| CD
.  ||| S:770 E:772 ||| .
Proportionally  ||| S:772 E:787 ||| RB
more  ||| S:787 E:792 ||| JJR
patients  ||| S:792 E:801 ||| NNS
with  ||| S:801 E:806 ||| IN
a  ||| S:806 E:808 ||| DT
CTO  ||| S:808 E:812 ||| NNP
are  ||| S:812 E:816 ||| VBP
prescribed  ||| S:816 E:827 ||| VBN
LAIs  ||| S:827 E:832 ||| JJ
rather  ||| S:832 E:839 ||| RB
than  ||| S:839 E:844 ||| IN
oral  ||| S:844 E:849 ||| JJ
SGAs ||| S:849 E:853 ||| NN
.  ||| S:853 E:855 ||| .
The  ||| S:855 E:859 ||| DT
relationship  ||| S:859 E:872 ||| NN
between  ||| S:872 E:880 ||| IN
receiving  ||| S:880 E:890 ||| VBG
an  ||| S:890 E:893 ||| DT
LAI  ||| S:893 E:897 ||| NNP
and  ||| S:897 E:901 ||| CC
being  ||| S:901 E:907 ||| VBG
subject  ||| S:907 E:915 ||| JJ
to  ||| S:915 E:918 ||| TO
a  ||| S:918 E:920 ||| DT
CTO  ||| S:920 E:924 ||| NNP
is  ||| S:924 E:927 ||| VBZ
significant ||| S:927 E:938 ||| JJ
,  ||| S:938 E:940 ||| ,
and  ||| S:940 E:944 ||| CC
reflects  ||| S:944 E:953 ||| VBZ
the  ||| S:953 E:957 ||| DT
consideration  ||| S:957 E:971 ||| NN
given  ||| S:971 E:977 ||| VBN
to  ||| S:977 E:980 ||| TO
enhancing  ||| S:980 E:990 ||| VB
adherence  ||| S:990 E:1000 ||| VBN
in  ||| S:1000 E:1003 ||| IN
a  ||| S:1003 E:1005 ||| DT
community  ||| S:1005 E:1015 ||| NN
mental  ||| S:1015 E:1022 ||| JJ
health  ||| S:1022 E:1029 ||| NN
setting ||| S:1029 E:1036 ||| NN
.  ||| S:1036 E:1038 ||| .
